Be a champion for change
A n estimated 50,000 people who die from cancer every year could still be alive if the quality of diagnosis and care in European countries with the poorest survival rates were as good as the median [more]
Number 82
A n estimated 50,000 people who die from cancer every year could still be alive if the quality of diagnosis and care in European countries with the poorest survival rates were as good as the median across Europe. That number rises... [ more ]
Improving outcomes – a practical guide
After 25 years of trying to improve the way we organise and deliver cancer care we now have a fairly clear idea about what changes are needed to get the best patient outcomes. Finding ways [more]
Reciprocity in informed consent: a fairer framework for first-in-human trials
Patients play an integral part in the clinical trial process that enables new treatments to be approved and adopted into clinical practice. Without patients, no trials can be undertaken, and thus no drugs can be [more]
Gut response: Does benefit from immunotherapy depend on the bacteria in our intestines?
A spate of recent studies suggest that differences in population of bacteria and other micro-organisms that inhabit our intestines may be a key factor differentiating between people who respond to immune checkpoint inhibitors and those [more]
Bahadir Güllüoğlu: driving up standards in Turkey towards the best in breast
As a young surgeon, Bahadir Güllüoğlu was drawn to specialising in breast cancer because of the opportunities that were opening up to work closely with other types of specialists, as well as with patients and [more]
Mind the gap! Who cares for patients after treatment is over?
Specialists feel responsible for their patients, but lack time to offer long-term care. Patients feel abandoned as their treatment ends, but lack resources to seek the care they need. GPs lack confidence to deal with [more]
Hereditary mutations in cancer: the use of panels and genetic counselling
Testing for hereditary mutations that increase the risk of cancer is important for risk reduction, early detection and choice of treatment. Ephrat Levy-Lahad offers an overview of what we know ‒ and what remains uncertain [more]
Personalised cancer medicine: What’s the evidence it works?
If we can only find out what is driving a given cancer and/or what mechanism is creating resistance to treatment, it should be possible to at least halt the progress of the tumour by blocking [more]
Negotiating a global cancer plan: the first two acts of a three-part drama
In recent years, a series of World Oncology Forums have brought cancer specialists together with global health organisations and national health policy makers from many countries to try to develop a global response that could [more]
Advanced Breast Cancer: what’s new in treatment and care?
Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in [more]
Annette Berendsen – Researcher, Oncology in Primary Care
Transferring more responsibility for the care of cancer patients and survivors from specialists to general practitioners (GPs) is seen as key to coping with rising patient numbers. GPs, specialists and patients question how this can [more]
Art and oncology: one life
Scientist or artist? Michael Peckham, who is best known for his contribution to the treatment of testicular cancer and Hodgkin lymphoma, and was involved in founding the European School of Oncology, refuses to choose and [more]